Blocking poly (ADP-ribose) polymerase (PARP) will selectively kill tumor cells with some types of DNA repair deficiencies, a vulnerability known as synthetic lethality. Read More
Presenting during the late-breaking clinical trial posters at Kidney Week in New Orleans, Reata Pharmaceuticals Inc. did not disappoint with primary 12-week data from the phase II portion of its CARDINAL trial of bardoxolone methyl (bard) to treat chronic kidney disease (CKD) caused by Alport syndrome. Read More
LONDON – Shares in Redx Pharma plc will start trading again on Monday at midday, five months after it was forced into administration after failing to repay a £3.5 million (US$4.6 million) loan from Liverpool City Council. Read More
TCR2 Therapeutics Inc., of Cambridge, Mass., named Andrew Cornforth vice president of process development; Daniel Getts vice president of research; and Alfonso Quintás chief medical officer. Read More
Alexion Pharmaceuticals Inc., of New Haven, Conn., reported new interim data from a trial testing Kanuma (sebelipase alfa) in patients with rapidly progressive lysosomal acid lipase deficiency at the NASPGHAN Annual Meeting in Las Vegas. Of the 10 infants treated with Kanuma, nine survived beyond 1 year of age, compared to a median age of death of 3.7 months with mortality by 1 year of nearly 100 percent for historically untreated infants. Read More
Valeant Pharmaceuticals International Inc., of Laval, Quebec, said subsidiary Bausch & Lomb and Sophia Antipolis, France-based Nicox SA gained FDA approval for Vyzulta (latanoprostene bunod ophthalmic solution, 0.024 percent) for the reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension. Bausch & Lomb in-licensed the program from Nicox in 2010. Read More
Cipher Pharmaceuticals Inc., of Mississauga, Ontario, said it entered a new three-year, $20 million senior secured term credit facility with Canadian Imperial Bank of Commerce. Read More
PALM SPRINGS, Calif. – At a health care conference devoted to big ideas that could shift the future of care, med-tech startups were front and center. They brought forth a vision of a range of innovative technologies: using gene-editing CRISPR for at-home diagnostics, machine learning for more accurate imaging interpretation, bioelectronics for chronic diseases, virtual reality for surgical training, and liquid biopsy to detect asymptomatic, age-related diseases. Read More
HONG KONG – Hutchison China Meditech Ltd. (Chi-Med) said the phase III trial of its oral vascular endothelial growth factor (VEGF) inhibitor fruquintinib has begun. Named FRUTIGA, the randomized, double-blind, placebo-controlled, multicenter study is to test fruquintinib's efficacy and safety in combination with chemotherapy paclitaxel for the treatment of advanced gastric cancer, or gastroesophageal junction adenocarcinoma, in China. Read More
In developing aducanumab, one of the more promising therapies for Alzheimer's disease (AD), Neurimmune Therapeutics AG took a creative approach – one that caught the eye of Biogen Inc. "Aducanumab actually comes from a human individual, someone who was in his or her late 90s or early 100s," Ajay Verma, previously with Cambridge, Mass.-based Biogen, told BioWorld. Read More
